ATE457163T1 - Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol - Google Patents

Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol

Info

Publication number
ATE457163T1
ATE457163T1 AT04735045T AT04735045T ATE457163T1 AT E457163 T1 ATE457163 T1 AT E457163T1 AT 04735045 T AT04735045 T AT 04735045T AT 04735045 T AT04735045 T AT 04735045T AT E457163 T1 ATE457163 T1 AT E457163T1
Authority
AT
Austria
Prior art keywords
ciclesonide
formoterol
maintain
particle size
fine particle
Prior art date
Application number
AT04735045T
Other languages
English (en)
Inventor
Nicholas Heaton
Zoe Heaton
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of ATE457163T1 publication Critical patent/ATE457163T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00Ancillary equipment
    • A61M2209/06Packaging for specific medical equipment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT04735045T 2003-05-28 2004-05-27 Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol ATE457163T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312148.0A GB0312148D0 (en) 2003-05-28 2003-05-28 Stabilized pharmaceutical products
PCT/GB2004/002249 WO2004105727A2 (en) 2003-05-28 2004-05-27 Stabilized pharmaceutical product

Publications (1)

Publication Number Publication Date
ATE457163T1 true ATE457163T1 (de) 2010-02-15

Family

ID=9958829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735045T ATE457163T1 (de) 2003-05-28 2004-05-27 Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol

Country Status (22)

Country Link
US (4) US7736673B2 (de)
EP (1) EP1626913B1 (de)
JP (1) JP5175048B2 (de)
KR (1) KR20060023539A (de)
CN (1) CN1832890A (de)
AR (1) AR047619A1 (de)
AT (1) ATE457163T1 (de)
AU (1) AU2004243223A1 (de)
BR (1) BRPI0410701A (de)
CA (1) CA2527088C (de)
DE (1) DE602004025463D1 (de)
ES (1) ES2340681T3 (de)
GB (1) GB0312148D0 (de)
MA (1) MA27804A1 (de)
MX (1) MXPA05012757A (de)
NO (1) NO20055443L (de)
PL (1) PL1626913T3 (de)
RS (1) RS20050882A (de)
RU (1) RU2337667C2 (de)
TW (1) TW200509989A (de)
WO (1) WO2004105727A2 (de)
ZA (1) ZA200509099B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (de) 2003-06-13 2006-03-22 ALTANA Pharma AG Kombination aus formoterol und ciclesonid
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
EP1803457A1 (de) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmazeutische Zubereitung, welche Montelukast enthält
SI1976522T2 (sl) * 2005-12-30 2019-11-29 Krka Tovarna Zdravil D D Novo Mesto Farmacevtski sestavek, ki vsebuje montelukast
US20090308772A1 (en) * 2006-03-17 2009-12-17 Abrams William S Moisture-tight primary packaging for a dry powder inhaler
CA2716124A1 (en) * 2008-02-20 2009-08-27 Boehringer Ingelheim International Gmbh Powder inhalers
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US9233788B2 (en) 2010-01-22 2016-01-12 Bayer Healthcare Llc Biosensor desiccant system having enhanced measurement performance
KR101783067B1 (ko) * 2010-01-22 2017-09-28 바이엘 헬쓰케어 엘엘씨 정확도 향상용 건조제
WO2011093814A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising formoterol and ciclesonide
EP3461474B1 (de) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Inhalationsmedikamente in trockenpulverform mit feuchtigkeitsregelungseigenschaften und verfahren zu ihrer verabreichung
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
TWI565943B (zh) * 2011-07-22 2017-01-11 拜耳保健公司 具有增進測量性能之生物感測器乾燥劑系統
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
WO2013109212A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
KR20130140358A (ko) 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
EP2954329A1 (de) 2013-02-05 2015-12-16 Nestec S.A. Verfahren zur auswahl einer kombinationstherapie für darmkrebspatienten
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
US11642309B2 (en) * 2017-10-16 2023-05-09 Faes Farma, S.A. Aqueous compositions comprising bilastine and mometasone
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
CA2410004A1 (en) 2000-05-23 2001-11-29 Glaxo Group Limited Aerosol container for formulations of salmeterol xinafoate
GB0015043D0 (en) * 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002177A0 (fi) 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
KR20050044503A (ko) 2001-11-17 2005-05-12 아벤티스 파마 리미티드 흡착제 및 이의 용도
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
JP2004051502A (ja) * 2002-07-17 2004-02-19 Jcr Pharmaceuticals Co Ltd 成長ホルモン含有安定化粉末製剤
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
JP2006528228A (ja) 2003-05-22 2006-12-14 アルタナ ファルマ アクチエンゲゼルシャフト サルメテロール及びシクレソニドの組合せ物
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
WO2005007853A2 (en) * 2003-06-06 2005-01-27 Senesco Technologies, Inc. Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
EP1635845A1 (de) 2003-06-13 2006-03-22 ALTANA Pharma AG Kombination aus formoterol und ciclesonid
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
JP5175048B2 (ja) 2013-04-03
US20120247982A1 (en) 2012-10-04
ZA200509099B (en) 2006-08-30
US20060147537A1 (en) 2006-07-06
MA27804A1 (fr) 2006-03-01
RU2005136869A (ru) 2006-06-10
RS20050882A (en) 2007-12-31
AU2004243223A1 (en) 2004-12-09
CN1832890A (zh) 2006-09-13
CA2527088C (en) 2011-03-01
MXPA05012757A (es) 2006-02-13
AR047619A1 (es) 2006-02-01
WO2004105727A2 (en) 2004-12-09
PL1626913T3 (pl) 2010-07-30
US20100247585A1 (en) 2010-09-30
EP1626913A2 (de) 2006-02-22
TW200509989A (en) 2005-03-16
DE602004025463D1 (de) 2010-03-25
US8163299B2 (en) 2012-04-24
US8029811B2 (en) 2011-10-04
EP1626913B1 (de) 2010-02-10
US7736673B2 (en) 2010-06-15
BRPI0410701A (pt) 2006-06-13
RU2337667C2 (ru) 2008-11-10
ES2340681T3 (es) 2010-06-08
US20110308975A1 (en) 2011-12-22
WO2004105727A3 (en) 2005-06-16
CA2527088A1 (en) 2004-12-09
JP2007504277A (ja) 2007-03-01
US8440210B2 (en) 2013-05-14
GB0312148D0 (en) 2003-07-02
KR20060023539A (ko) 2006-03-14
NO20055443L (no) 2005-11-17

Similar Documents

Publication Publication Date Title
ATE457163T1 (de) Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol
ATE465712T1 (de) Ultrafeine zusammensetzungen von formoterol
SI1594867T1 (sl) Fenilacetamidi in njihova uporaba kot glukokinazni modulatorji
DE502004001052D1 (de) Verwendung von polysilazan zur herstellung von hydrophob- und oleophobmodifizierten oberflächen
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
IL188151A0 (en) ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
GB0605251D0 (en) Well treating compositions containing water-super absorbent material and method of using the same
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
ATE434983T1 (de) Vorrichtung zur elastischen stabilisierung von wirbelkörpern
IL181689A0 (en) Aptamers to von willebrand factor and pharmaceutical compositions containing the same
DE602005006062D1 (de) Plättchenförmige Komposit-Partikeln und Kosmetika enthaltend die selben
DE602004010708D1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
ATE388635T1 (de) Verwendung von menadione zur verstärkung der wirksamkeit von agrochemikalien
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
ATE435593T1 (de) Verwendung von ozon zur verbesserung des knetvorgangs
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
IL174827A0 (en) Antibodies to nik preparation and use
DE602006007995D1 (de) Formulierungen von liponsäure und hyaluronsäurebeneichen
HK1079776A1 (en) The synthesis of 1,3-dihydro-2h-3-benzazepin-2-onecompounds, and the use thereof
DE502006003030D1 (de) Verwendung von inhibitoren des na+/h+ austauschers, subtyp 5 (nhe5) zur gedächtnisverbesserung
SE0203057L (sv) Uppfinning som visar platsen i asfaltverkets blandare där finfraktionenes material skall tillsättas
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties